Caprius Receives Payment of $1.1 Million in Resolution of Patent Issues.

WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 8, 1998--Caprius, Inc. (Nasdaq: CAPR) announced today that it had received $1.1 million from a major MRI manufacturer to resolve outstanding patent issues unrelated to the patents protecting its Aurora(R) technology.

"This infusion of funds will allow us to dedicate more resources to the development and expansion of our program to acquire comprehensive breast imaging centers," stated Jack Nelson, Chairman and CEO of Caprius. "With the success we are experiencing at our Strax Center in Florida, we are convinced that pursuing a strategy of further acquisitions will benefit our shareholders. This transaction and the transaction contemplated in the letter of intent announced last week for the sale of our technology based assets, provides us the additional resources to pursue this objective."

Caprius, Inc. has signed a letter of intent with Mi3 and Ampersand Ventures to sell its Aurora technology assets and will also receive a royalty stream from future Aurora sales. The Company expects to realize approximately $5 million from the sale and future royalties. Mi3 and Ampersand will also assume all ongoing liabilities and debt connected to the technology. The agreement is non-binding in nature, with the exception of certain provisions granting the acquirers an exclusive negotiating period through January 13, 1999 and dealing with expenses, publicity and timing. Any transaction would be subject to, among other conditions, Board approval, the completion of definitive agreements and due diligence by the acquirers. Accordingly, there can be no assurance that a definitive agreement will be entered into or any transactions will be completed.

Safe Harbor Statement:

The statements made in this press release that are not historical fact are "forward-looking statements" which are based upon current expectations that include a number of risks and uncertainties. Factors that could cause actual results to differ materially from the forward -looking statements include meeting ordinary and customary closing conditions, delays in product development, lack of market acceptance of technology, technological innovations of competitors and changes in health care regulations, including reimbursement programs.